Dayvigo 5 & 10 5 mg, 10 mg Tablet
PDF Leaflet Revision Date: 10 January 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of adult patients with insomnia.
Dosage (summary)
5 mg once nightly before bed; may increase to 10 mg based on response.
Special Populations
- Hepatic impairment
- Elderly
- Renal impairment
Pregnancy & Breastfeeding
Not recommended in pregnancy; safety during breastfeeding not established.
Key Drug Interactions
- Strong/moderate CYP3A inhibitors
- Strong/moderate CYP3A inducers
- Alcohol
Contraindications
- Hypersensitivity to lemborexant
- Narcolepsy
Common side effects
- Somnolence
- Headache
- Nightmares
Counselling Points
- Avoid alcohol while taking DAYVIGO.
- Caution against driving or operating machinery.
- Monitor for signs of complex sleep behaviours.
Serious warnings
- CNS depressant effects
- Risk of daytime impairment
- Worsening of depression/suicidal ideation
Important Disclaimer
The Dayvigo 5 & 10 5 mg, 10 mg Tablet professional information leaflet below is the property of Eisai Pharmaceuticals Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
